- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT03008616
Study of the Efficacy and Safety of AMAG-423 (Digoxin Immune Fab) in Antepartum Subjects With Severe Preeclampsia
March 31, 2022 updated by: AMAG Pharmaceuticals, Inc.
A Phase 2b/3a, Multi-Center, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study of the Efficacy and Safety of AMAG-423, a Digoxin Immune Fab, in Antepartum Subjects With Severe Preeclampsia
This study evaluates the use of AMAG-423 (Digoxin Immune Fab) in addition to expectant management in the treatment of severe preeclampsia as compared to placebo.
Study Overview
Status
Terminated
Conditions
Intervention / Treatment
Study Type
Interventional
Enrollment (Actual)
59
Phase
- Phase 2
- Phase 3
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
Pomorskie
-
Gdansk, Pomorskie, Poland, 80-462
- Adalbertus Hospital
-
-
-
-
Gauteng
-
Pretoria, Gauteng, South Africa, 0204
- Sefako Makgatho Health Sciences University
-
-
-
-
Alabama
-
Mobile, Alabama, United States, 36604
- University of South Alabama
-
-
Kansas
-
Kansas City, Kansas, United States, 66160
- University of Kansas Medical Center
-
-
Kentucky
-
Louisville, Kentucky, United States, 40202
- Children's Hospital Foundation Building
-
-
Louisiana
-
New Orleans, Louisiana, United States, 70112
- Louisiana State University Health Sciences Center in New Orleans
-
-
Maryland
-
Baltimore, Maryland, United States, 21201
- University of Maryland
-
-
Michigan
-
Detroit, Michigan, United States, 48201
- Detroit Medical Center (DMC)
-
-
Mississippi
-
Jackson, Mississippi, United States, 39216
- University of Mississippi Medical Center
-
-
Ohio
-
Cincinnati, Ohio, United States, 45219
- University of Cincinnati Medical Center
-
Cleveland, Ohio, United States, 44106
- University Hospitals Case Medical Center-Case Western Reserve University (CWRU)
-
-
Tennessee
-
Chattanooga, Tennessee, United States, 37403
- Regional Obstetrical Consultants
-
-
Texas
-
Galveston, Texas, United States, 77555
- The University of Texas Medical Branch (UTMB)
-
Houston, Texas, United States, 77030
- Texas Children's Hospital/Baylor College of Medicine
-
Houston, Texas, United States, 77303
- The University of Texas Health Science Center at Houston (UTHSC-H)
-
Temple, Texas, United States, 76508
- Baylor Scott & White Health
-
-
Virginia
-
Charlottesville, Virginia, United States, 29208
- University of Virginia School of Medicine
-
-
Wisconsin
-
Milwaukee, Wisconsin, United States, 53226
- Medical College Of Wisconsin
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
16 years and older (Adult, Older Adult)
Accepts Healthy Volunteers
No
Genders Eligible for Study
Female
Description
Inclusion Criteria:
- Fetal gestational age 23 0/7 to 31 6/7 weeks
- Treated with expectant management
- Meets modified ACOG criteria for severe preeclampsia
- Willing and able to provide written, informed consent
Exclusion Criteria:
- Decision to deliver within 24 hours has been made
- Weight > 150 kg
- Eclampsia
- Significant antecedent obstetrical problems
- Clinically significant fetal anomaly or chromosomal abnormalities
- Chronic renal disease
- Active hepatic disease, antiphospholipid antibody syndrome, or lupus
- Unstable medical or psychiatric disorder
- Need for use of digitalis like products
- History of anaphylactic allergic reactions
- Prior use of antibodies/fab fragments from sheep
- Serum creatinine ≥ 2.0 mg/dL
- Platelet count < 50,000
- Pulmonary edema
- Estimated fetal weight < 5th percentile
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Quadruple
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Active Comparator: AMAG-423 (digoxin immune fab)
AMAG-423 (digoxin immune fab) 3.2 mg/kg, 30 minute IV infusion, every 6 hours x 4 days
|
AMAG-423 (digoxin immune fab) 3.2 mg/kg, 30 minute IV infusion, every 6 hours x 4 days
Other Names:
|
Placebo Comparator: Placebo
Normal saline, 30 minute IV infusion, every 6 hours x 4 days
|
Normal saline, 30 minute IV infusion, every 6 hours x 4 days
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Proportion of infants who have severe IVH, NEC, or death by 36 weeks corrected gestational age
Time Frame: 36 weeks corrected gestational age
|
Proportion of infants who have severe IVH, NEC, or death by 36 weeks corrected gestational age
|
36 weeks corrected gestational age
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Change from baseline in serum creatinine
Time Frame: From treatment initiation to 24 hours post first dose
|
Maternal change from baseline in serum creatinine to 24 hours post first dose
|
From treatment initiation to 24 hours post first dose
|
Incidence of pulmonary edema
Time Frame: From treatment initiation until completion of treatment phase (up to 4 days)
|
Maternal incidence of pulmonary edema during the treatment period
|
From treatment initiation until completion of treatment phase (up to 4 days)
|
Proportion of mothers with modified early obstetric warning score >= 3 at 24 hours post first dose
Time Frame: 24 hours post first dose
|
Proportion of mothers with modified early obstetric warning score >= 3 at 24 hours post final dose
|
24 hours post first dose
|
Delivery latency
Time Frame: From treatment initiation until delivery
|
Time from start of treatment until delivery
|
From treatment initiation until delivery
|
Anti-hypertensive use during treatment
Time Frame: From treatment initiation until completion of treatment phase (up to 4 days)
|
Use of or change in anti-hypertensive use during the treatment period
|
From treatment initiation until completion of treatment phase (up to 4 days)
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Actual)
April 12, 2017
Primary Completion (Actual)
August 13, 2020
Study Completion (Actual)
August 13, 2020
Study Registration Dates
First Submitted
December 20, 2016
First Submitted That Met QC Criteria
December 29, 2016
First Posted (Estimate)
January 2, 2017
Study Record Updates
Last Update Posted (Actual)
April 4, 2022
Last Update Submitted That Met QC Criteria
March 31, 2022
Last Verified
March 1, 2022
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- AMAG-423-201
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
No
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Yes
Studies a U.S. FDA-regulated device product
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Severe Preeclampsia
-
University Medical Centre LjubljanaCompletedPreeclampsia Postpartum | Preeclampsia SevereSlovenia
-
MemorialCare Health SystemNot yet recruitingPreeclampsia | Preeclampsia Postpartum | Preeclampsia Severe | Preeclampsia Mild
-
Mpilo Central HospitalCompletedSevere PreeclampsiaZimbabwe
-
Instituto Materno Infantil Prof. Fernando FigueiraCompletedSevere PreeclampsiaBrazil
-
Corniche HospitalCompletedPreeclampsia SevereUnited Arab Emirates
-
Hopital Antoine BeclereUnknownPreeclampsia SevereFrance
-
Saint Thomas Hospital, PanamaCompleted
-
Peking University Third HospitalBeijing Forestry universityEnrolling by invitation
-
Ain Shams UniversityUnknown
-
Cairo UniversityUnknown
Clinical Trials on AMAG-423 (digoxin immune fab)
-
National Institute on Aging (NIA)University of Toledo Health Science CampusUnknownHypertension | HemodialysisUnited States
-
University of Maryland, BaltimoreRecruiting
-
BTG International Inc.GlaxoSmithKlineCompleted
-
BTG International Inc.Completed
-
Wake Forest University Health SciencesTerminatedSnake EnvenomationUnited States
-
Instituto Bioclon S.A. de C.V.University of Arizona; Universidad Nacional Autonoma de MexicoCompleted
-
Mirati Therapeutics Inc.CompletedAdvanced Solid TumorUnited States